Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12104/40912
Title: Micronucleated erythrocytes in newborn rats exposed to raltegravir placental transfer
Author: Ibarra-Hurtado, T.R.
Nuno-Guzman, C.M.
Miranda-Diaz, A.G.
Troyo-Sanroman, R.
Navarro-Ibarra, R.
Bravo-Cuellar, L.
Issue Date: 2014
Abstract: Purpose: Abdominal wall hernia secondary to open abdomen management represents a surgical challenge. The hernia worsens due to lateral muscle retraction. Our objective was to evaluate if Botulinum Toxin Type A (BTA) application in lateral abdominal wall muscles modifies its thickness and length.Methods: A clinical trial of male trauma patients with hernia secondary to open abdomen management was performed from January 2009 to July 2011. Thickness and length of lateral abdominal muscles were measured by a basal Computed Tomography and 1 month after BTA application. A dosage of 250 units of BTA was applied at five points at each side between the external and internal oblique muscles under ultrasonographic guidance. Statistical analysis for differences between basal and after BTA application measures was performed by a paired Studentés t test (significance: p < 0.05).Results: Seventeen male patients with a mean age of 35 years were included. There were muscle measure modifications in all the patients. Left muscle thickness: mean reduction of 1 0.55 cm (p < 0.001). Right muscle thickness: mean reduction of 1.00 0.49 cm (p < 0.001). Left muscle length: mean increase of 2.44 1.22 cm (p < 0.001). Right muscle length: mean increase of 2.59 1.38 cm (p < 0.001). No complications secondary to BTA or recurrences at mean follow-up of 49 months were observed.Conclusions: BTA application in lateral abdominal muscles decreases its thickness and increases its length in abdominal wall hernia patients secondary to open abdomen management. " 2014, Springer-Verlag France.",,,,,,"10.1007/s10029-014-1280-2",,,"http://hdl.handle.net/20.500.12104/40912","http://www.scopus.com/inward/record.url?eid=2-s2.0-84919451310&partnerID=40&md5=0a95422d5ff4653b2a1daca73ece0662",,,,,,"5",,"Hernia",,"647
652",,"18",,"Scopus
WOS",,,,,,"Abdominal wall; Botulinum toxin type A; Incisional hernia; Open abdomen management",,,,,,"Effect of botulinum toxin type A in lateral abdominal wall muscles thickness and length of patients with midline incisional hernia secondary to open abdomen management",,"Article" "44606","123456789/35008",,"Torres-Mendoza, B.M., División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano Del Seguro Social, 44340 Guadalajara, JAL, Mexico, Departamento de Clínicas Médicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44350 Guadalajara, JAL, Mexico; Coronado-Medina, D.E., División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano Del Seguro Social, 44340 Guadalajara, JAL, Mexico, Maestría en Nutrición Clínica, Universidad Del Valle de Atemajac, 45050 Zapopan, JAL, Mexico; Gómez-Meda, B.C., Departamento de Biología Molecular y Genómica, Instituto de Biología Molecular en Medicina y Terapia Gúnica, Universidad de Guadalajara, 44350 Guadalajara, JAL, Mexico; Vázquez-Valls, E., Unidad Médica de Alta Especialidad, Hospital de Especialidades, Instituto Mexicano Del Seguro Social, 44340 Guadalajara, JAL, Mexico; Zamora-Perez, A.L., Departamento de Clínicas Odontológicas Integrales, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44350 Guadalajara, JAL, Mexico; Lemus-Varela, M.D.L., Departamento de Neonatología, Unidad Médica de Alta Especialidad, Instituto Mexicano Del Seguro Social, 44340 Guadalajara, JAL, Mexico; Zúñiga-González, G.M., Laboratorio de Mutagénesis, Centro de Investigación Biomédica de Occidente, Instituto Mexicano Del Seguro Social, Sierra Mojada 800, Colonia-Independencia-44340-Guadalajara-JAL, Mexico",,"Torres-Mendoza, B.M.
Coronado-Medina, D.E.
Gomez-Meda, B.C.
Vazquez-Valls, E.
Zamora-Perez, A.L.
Lemus-Varela, M.D.L.
Zuniga-Gonzalez, G.M.",,"2014",,"The use of raltegravir in treating HIV/AIDS has been proposed due to its effectiveness in suppressing high loads of HIV RNA in pregnant women, thus preventing infection of the fetus. However, administration of raltegravir during pregnancy produces a compound which is transferred to high concentrations to the offspring. The objective of this study is to evaluate the transplacental genotoxic effect of raltegravir in newborn rats. We evaluated the number of micronucleated erythrocytes (MNE), micronucleated polychromatic erythrocytes (MNPCE), and polychromatic erythrocytes (PCE) in the peripheral blood samples of the offspring of Wistar rats treated 6 days before birth with oral administration of raltegravir. The animals were randomly assigned to five groups as follows: raltegravir at doses of 15, 30, or 60 mg/day, cyclophosphamide 10 mg/kg (positive control), or 0.5 ml of sterile water (negative control). In addition, the effect of these drugs on the weight and height of newborns was assessed. There were no differences in the number of MNE, MNPCE, and PCE, and a slight decrease in the weight and height was observed in the offspring of the rat mothers treated with raltegravir. Genotoxicity studies are required in pregnant women to determine the risk of using raltegravir to the fetuses. " 2014 Blanca Miriam Torres-Mendoza et al.
URI: http://hdl.handle.net/20.500.12104/42827
http://www.scopus.com/inward/record.url?eid=2-s2.0-84902145168&partnerID=40&md5=82dc96af336dae478cf269d72a36e2df
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=prem&AN=24977162
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.


Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.